Life Sciences
Below are all our articles under the above category.
Avita Medical (ASX:AVH): It hasn’t catapulted it to the heights envisioned (yet), but there’s hope for the 2026 and 2027
Avita Medical (ASX:AVH/NDQ:RCEL) is a particularly peculiar healthcare stock. The company, these days based in the Californian city of Valencia…
Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer
$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through ‘blockbuster drugs’ with periods of market exclusivity, which…
Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?
The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived…
PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!
PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect…
Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism
Cyclopharm (ASX:CYC) is a rare species – an ASX stock that is approved in the US market. However, its share…
Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for
Hear the term ‘Activist investors’ and you might think of GetUp, the progressive activist group that forced Woolworths to hold…
Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd
Proteomics‘ suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been…
Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor
Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a…
Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX
There’s another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed…
Emyria’s (ASX:EMD) commercial breakthrough in psychedelic medicine
When Perth-based Emyria (ASX:EMD) announced on 18 June that Medibank would be funding eligible customer participation in Emyria’s Post-Traumatic Stress…
Actinogen Medical (ASX:ACW): Will history repeat itself? Can it bounce back from a troublesome Phase 2 trial?
Actinogen Medical (ASX:ACW) is the poster child for how volatile biotech stocks can be. the last time we wrote about…
Zeotech (ASX:ZEO): Stronger and low-carbon concrete derived from Queensland kaolin!
Zeotech (ASX:ZEO) is attempting to play a part in helping reduce emissions from the construction sector. Over the last few…
4D Medical (ASX:4DX) could become the next Pro Medicus, and its taken some important strides in 2025!
There’s not many Australian radiology companies that seek to conquer the USA, but 4D Medical (ASX:4DX) is one of them.…
ASX stocks in America: Here are 4 performing well and 4 performing poorly
You might think ASX stocks in America are doing better than peers which are not there because the USA is…
Blinklab (ASX:BB1): Is this exciting company the next ResApp?
Blinklab (ASX:BB1) is the answer to the question of how you could help children with autism – a response that…
Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?
Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if…
Here are 5 ASX biotechs expecting clinical trial results in the next few months!
Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the…
6 of the best annual results on the ASX in FY25 and 6 of the worst!
Each reporting season, we like to recap some of the best annual results on the ASX and some of the…
As ASX Reporting Season for FY25 Looms: Here’s An Investors Ultimate Guide
ASX Reporting Season is almost upon us once again. It is the most important time of the year for investors,…
Is it possible for an investor to ‘time the market’ or is it just a myth?
Is it possible at all to time the market? Some will tell you it is possible, but they were probably…
Here Are 4 Dogs of the ASX that will Bounce Back With a Vengeance in FY26, and 4 That Won’t
Have you ever heard the term Dogs of the ASX? It can either allude to the worst stocks in the…
Percheron Therapeutics (ASX:PER) picks itself up in 2025
Percheron Therapeutics (ASX:PER) It’s a fact of life in the biotech game: drugs often fail in clinical development. Percheron Therapeutics…
Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!
It is a New Financial Year, so it’s time to outline 11 Top ASX Stocks to Buy in FY26. Why…
When investors are in a risk off mindset: Here are the 5 moves they usually make and why
Israel’s strikes on Iran, and the subsequent responses, led to the typical “risk off” moves professional investors usually make when…
How to stop the ASX decline? ASIC and investors have some radical ideas
Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left…
Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so
Will Ozempic hurt healthcare stocks? Investors who’ve been selling healthcare stocks left right and centre – except Novo Nordisk of…
ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?
ESG investing is becoming increasingly popular with investors. But as this happens, it begs the question as to just how you…
This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true
‘The investor who says, “This time is different,” when in fact it’s virtually a repeat of an earlier situation, has…
Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know
After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he…
The equity markets in 2025 may rebound hard, according to this scenario
There’s hope for equity markets in 2025 When the market is crashing as hard as it has been doing in…
Should you use your tax cut to invest in stocks? And how should you go about it?
Should you use your tax cut to invest in stocks? With another unexpected round of tax cuts starting from the…
Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!
Recce Pharmaceuticals (ASX:RCE) has completed its Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections) for RECCE® 327…
Here’s how Australia’s Research and Development Tax Incentive Works
Australia’s Research and Development Tax Incentive (R&D Tax Incentive) regime can be useful for pre-commercialisation companies serving as a non-dilutive…
Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m
Alterity Therapeutics (ASX:ATH) hit the jackpot last week. Any clinical-stage biotech achieving a positive Phase 2 outcome is good news,…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!
Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing’s first. We know this…
Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!
Here are our 6 Best ASX Stocks for 2025! Opthea (ASX:OPT) Its been a long wait, but 2025 will…
Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!
Proteomics (ASX:PIQ) is one of the healthcare stocks to watch in CY25, because it has not one, not two, but…
Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!
Investors were evidently pleased with the results out of Island Pharmaceuticals‘ PROTECT clinical trial…at least if the company’s more than…
Here are 6 ASX CEOs who departed their companies in 2024
Here are 6 ASX CEOs who departed their companies in 2024 Larry Diamond – Zip (ASX:ZIP) Since Afterpay’s acquisition, Zip…
These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!
There are 2 key milestones awaiting Recce Pharmaceuticals (ASX:RCE) in the next few months that investors in this company need…
The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off
Nearly a year since the $8.8bn Chemist Warehouse Sigma merger was unveiled, it seems we finally got a definitive answer…
Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results
There are encouraging signs from Recce Pharmaceuticals‘ (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections).…
Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months
Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and…
Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!
Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons…
Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!
The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced…
Here Are The Top 5 Websites for Stock Market News & Analysis in Australia
For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range…
Here are 4 economic indicators that impact stocks and investors must pay attention to
There are several economic indicators that impact stocks, both on the ASX and internationally. Whenever data is released, it can…
As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts
Here 6 ASX stocks that will benefit from lower interest rates! AGL Energy (ASX:AGL) You might think AGL is…
Here’s why investors fear a US recession, and whether the fears are justified
Investors fear a US recession – there’s no denying it and there’s no other explanation for the market correction in…
Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?
After a decade of nothing but good news for investors in CSL (ASX:CSL), shares fell by ~25% between June and…
Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?
In the past year, biotech shares have performed poorly. Why has this been the case and will things be better…
Which ASX health stocks might get FDA approval in 2023?
It is the dream of many ASX health stocks and their investors for their company’s device or drug to be…
Immutep (ASX: IMM) has massive potential!
Immutep (ASX: IMM) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at…
Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock
Working on a new drug for Alzheimer’s disease Actinogen Medical (ASX: ACW) is a Sydney-based biotechnology company working on finding…
Pfizer delivers the goods on a COVID-19 vaccine
10 November 2020 One of the reasons investors can be optimistic about 2021 is the speed with which the first…